title: Intrauterine transfusions affect fetal T-cell immunity.
abstract: Intrauterine transfusion (IUT) therapy is the treatment of choice in severe hemolytic disease of the fetus. This treatment automatically implies the introduction of alloantigens in the fetal circulation, which might potentially influence the unprimed fetal immune system. The present study provides evidence that the fetal immune system is indeed prone to modulations of the T-cell receptor BV (TCRBV) repertoire as a result of IUT treatment. Most notably, IUT therapy affects the composition of the CD4+ repertoire, whereas this effect may be obscured in the CD8+ subset. The CD8+ subset was found to be influenced by alterations of the TCRBV repertoire both in IUT patients and controls, suggesting that modulations in this subset could be the result of developmental influences. A more detailed analysis on the composition of the individual TCRBV families was performed by evaluating the distribution of the complementarity determining region 3 (CDR3) size lengths of [32P]-radiolabeled TCRBV transcripts. Using this technique, referred to as spectratyping, only marginal changes were observed in the CD4+ and CD8+ subset during the course of treatment and gestational development of both IUT-treated patients and controls. Therefore, the alterations in the overall TCRBV repertoire were of a quantitative rather than a qualitative nature. To evaluate whether the observed alterations in TCRBV usage-frequencies were a reflection of an allo-reactive response, a primed lymphocyte test (PLT) was performed in 3 IUT-treated patients. We observed that IUT, performed as early as 23 weeks of gestation, may induce the establishment of memory T cells against the IUT donor. However, there was no association between the observed changes in TCRBV repertoire and the magnitude of the secondary allo-reactive response.
authors.affiliation: Department of Obstetrics, University Hospital Leiden, The Netherlands.
authors.forename: H E
authors.initials: HE
authors.lastname: Viëtor
authors.forename: G E
authors.initials: GE
authors.lastname: Hawes
authors.forename: C
authors.initials: C
authors.lastname: van den Oever
authors.forename: E
authors.initials: E
authors.lastname: van Beelen
authors.forename: H H
authors.initials: HH
authors.lastname: Kanhai
authors.forename: A
authors.initials: A
authors.lastname: Brand
authors.forename: P J
authors.initials: PJ
authors.lastname: Van den Elsen
mesh_terms: D001805:Blood Transfusion, Intrauterine; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004899:Erythroblastosis, Fetal / Q000628:therapy*; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005333:Fetus / Q000276:immunology; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D005796:Genes; D006684:HLA-DR Antigens / Q000276:immunology; D006648:Histocompatibility; D006801:Humans; D007231:Infant, Newborn; D008213:Lymphocyte Activation; D011247:Pregnancy; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D006684:HLA-DR Antigens; D016693:Receptors, Antigen, T-Cell, alpha-beta